Fulcrum Therapeutics Inc-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Fulcrum Therapeutics Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013418
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:18
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Fulcrum Therapeutics Inc (Fulcrum Therapeutics) is a biotechnology company which focuses on the discovery and development of small molecule therapies to unlock the gene control. Its pipeline portfolio includes Fragile X syndrome (FXS) and facioscapulohumeral muscular dystrophy (FSHD). Fulcrum’s product engine intends to develop disease-modifying therapies for various diseases across therapeutic areas such as Central Nervous System, Neuromuscular and Cardiovascular, among others. The company will also focuses on monogenic diseases which occur due to a faulty regulation of a single gene. Fulcrum Therapeutics is headquartered in Cambridge, Massachusetts, the US.

Fulcrum Therapeutics Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Fulcrum Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Fulcrum Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Fulcrum Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Fulcrum Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Fulcrum Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Fulcrum Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Fulcrum Therapeutics Raises Additional Funds through Series A Financing 10
Fulcrum Therapeutics Raises USD55 Million in Series A Financing 11
Partnerships 12
Horizon Discovery Enters into Agreement with Fulcrum Therapeutics 12
Fulcrum Therapeutics Inc – Key Competitors 13
Fulcrum Therapeutics Inc – Key Employees 14
Fulcrum Therapeutics Inc – Locations And Subsidiaries 15
Head Office 15
Recent Developments 16
Corporate Communications 16
May 03, 2017: Fulcrum Therapeutics Expands Leadership Team with Appointment of Owen Wallace, Ph.D., as Chief Scientific Officer and Amit Hasija as Chief Business Officer 16
Feb 07, 2017: Fulcrum Therapeutics Strengthens its Board of Directors with the Addition of Alan Ezekowitz, MBChB, D.Phil., and James J. Collins, Ph.D. 17
Appendix 18
Methodology 18
About GlobalData 18
Contact Us 18
Disclaimer 18

List of Tables
Fulcrum Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts 2
Fulcrum Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Fulcrum Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Fulcrum Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Fulcrum Therapeutics Inc, Deals By Therapy Area, 2011 to YTD 2017 8
Fulcrum Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Fulcrum Therapeutics Raises Additional Funds through Series A Financing 10
Fulcrum Therapeutics Raises USD55 Million in Series A Financing 11
Horizon Discovery Enters into Agreement with Fulcrum Therapeutics 12
Fulcrum Therapeutics Inc, Key Competitors 13
Fulcrum Therapeutics Inc, Key Employees 14

★海外企業調査レポート[Fulcrum Therapeutics Inc-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Curetis NV (CURE):企業の財務・戦略的SWOT分析
    Summary Curetis NV (Curetis) is a medical device company that offers molecular diagnosis solutions. The company provides diagnostic systems developed with Unyvero platform for severe infectious diseases. Its products are used in rapid diagnosis for cartridges, diseases such as implant and tissue inf …
  • PT Dian Swastatika Sentosa Tbk (DSSA):企業の財務・戦略的SWOT分析
    PT Dian Swastatika Sentosa Tbk (DSSA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths an …
  • ViroGates AS:医療機器:M&Aディール及び事業提携情報
    Summary ViroGates AS (ViroGates) is a meditech company that offers prognostic products. The company develops a prognostic biomarker to make the suPAR test presented as a commercially available test. Its products comprise measures suPAR, quick triage and ELISA. ViroGates’ suparnostic products offer a …
  • Electrabel SA-エネルギー分野:企業M&A・提携分析
    Summary Electrabel S.A. (Electrabel) is an energy utility company. It produces and sells electricity; supplies natural gas; and provides related energy products and services. The company operates diversified electricity generating facilities such as thermal, nuclear and renewable power plants, inclu …
  • St. Jude Children’s Research Hospital Inc-製薬・医療分野:企業M&A・提携分析
    Summary St. Jude Children’s Research Hospital Inc (St. Jude) is a healthcare service provider that offers research and clinical care services for children with catastrophic diseases. The hospital provides treatment programs such as brain tumors, leukemia, infectious diseases, immunodeficiency diseas …
  • The Siam Cement Public Co Ltd:戦略・SWOT・企業財務分析
    The Siam Cement Public Co Ltd - Strategy, SWOT and Corporate Finance Report Summary The Siam Cement Public Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Weifa ASA (WEIFA)-製薬・医療分野:企業M&A・提携分析
    Summary Weifa ASA (Weifa), formerly Aqualis ASA, is a pharmaceutical company that conducts the research and development, manufacture, distribution and sales of pharmaceutical products, lifestyle products and solutions. The company has over the counter (OTC) pharmaceutical market in Norway offering p …
  • Eastman Chemical Company:企業のM&A・事業提携・投資動向
    Eastman Chemical Company - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Eastman Chemical Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisiti …
  • Teachers Mutual Bank Ltd:企業の戦略的SWOT分析
    Teachers Mutual Bank Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • Powszechny Zaklad Ubezpieczen Group:戦略・SWOT・企業財務分析
    Powszechny Zaklad Ubezpieczen Group - Strategy, SWOT and Corporate Finance Report Summary Powszechny Zaklad Ubezpieczen Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, …
  • Edan Instruments Inc (300206):企業の製品パイプライン分析2018
    Summary Edan Instruments Inc (Edan Instruments) is a medical equipment provider that offers ECG equipments. The company offers diagnostic ECG, patient monitoring devices, obstetrics and gynaecology monitoring systems, ultrasound imaging, point-of-care testing, in-vitro diagnostics and veterinary equ …
  • Transgene SA (TNG):製薬・医療:M&Aディール及び事業提携情報
    Summary Transgene SA (Transgene), a subsidiary of Institut Merieux SA, is a biotechnology company that offers discovery and development of immunotherapies in the areas of cancer and infectious diseases. The company offers products such as therapeutic vaccines and oncolytic viruses. It develops targe …
  • Paz Oil Co Ltd (PZOL):企業の財務・戦略的SWOT分析
    Paz Oil Co Ltd (PZOL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • E.ON UK Plc:企業の戦略的SWOT分析
    E.ON UK Plc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Suzlon Energy Ltd (SUZLON):企業の財務・戦略的SWOT分析
    Suzlon Energy Ltd (SUZLON) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • First Gen Corporation:発電所・企業SWOT分析
    First Gen Corporation - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employe …
  • The Chugoku Bank Ltd:企業の戦略・SWOT・財務情報
    The Chugoku Bank Ltd - Strategy, SWOT and Corporate Finance Report Summary The Chugoku Bank Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • University of Birmingham-製薬・医療分野:企業M&A・提携分析
    Summary University of Birmingham is an academic research university that offers educational services. The university provides undergraduate, postgraduate, postgraduate research, and distance learning programs. It offers educational courses in various fields including accounting, astronomy, computer …
  • Shree Rama Newsprint Limited (RAMANEWS):企業の財務・戦略的SWOT分析
    Shree Rama Newsprint Limited (RAMANEWS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • Repros Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Repros Therapeutics Inc (Repros), formerly Zonagen Inc, a subsidiary of Allergan PLC, is a biopharmaceutical company that develops and markets drugs to treat hormonal and reproductive system disorders. The company’s pipeline product includes enclomiphene and proellex. Its enclomiphene is an …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆